A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Mutation research

• Publication date

  1997-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1383-5726(97)00004-6PMID 9360634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.

  1996cited by this paper
• Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes.

  1995cited by this paper
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

  1994cited by this paper
• It was a very good year for DNA repair.

  1994cited by this paper
• Where transcription meets repair.

  1994cited by this paper
• Mechanisms of DNA excision repair.

  1994cited by this paper
• The genetic defect in DNA repair deficiency syndromes. EACR--Mühlbock Memorial Lecture, 1993.

  1993cited by this paper
• Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning

  1993cited by this paper
• Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

  1993cited by this paper
• Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

  1993cited by this paper
• Expression of excision repair genes in non-malignant bone marrow from cancer patients.

  1993cited by this paper
• Effects of consecutive AGG codons on translation in Escherichia coli, demonstrated with a versatile codon test system

  1993cited by this paper
• Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines

  1992cited by this paper
• p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.

  1991cited by this paper
• Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells.

  1991cited by this paper
• Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

  1991cited by this paper
• Frequent mutation of the p53 gene in human esophageal cancer.

  1990cited by this paper
• Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.

  1989cited by this paper
• Codon usage determines translation rate in Escherichia coli.

  1989cited by this paper
• Characterization of Genes and Proteins Involved in Excision Repair of Human Cells

  1987cited by this paper
• Genomic characterization of the human DNA excision repair gene ERCC-1.

  1987cited by this paper
• Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10.

  1986cited by this paper
• Synthetic oligonucleotide probes deduced from amino acid sequence data. Theoretical and practical considerations.

  1985cited by this paper
• DNA sequences from the str operon of Escherichia coli.

  1980cited by this paper

• Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available NGS Data.

  2026cites this paper
• Genomic instability in ovarian cancer: Through the lens of single nucleotide polymorphisms.

  2024cites this paper
• Genetic polymorphisms in DNA repair genes and hepatocellular carcinoma risk.

  2021cites this paper
• ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent

  2021cites this paper
• ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

  2021cites this paper
• The ECCR1 rs11615, ERCC4 rs2276466, XPC rs2228000 and XPC rs2228001 polymorphisms increase the cervical cancer risk and aggressiveness in the Bangladeshi population

  2021cites this paper
• Clinical Perspectives of ERCC1 in Bladder Cancer

  2020cites this paper
• Role of common ERCC1 polymorphisms in cisplatin‐resistant epithelial ovarian cancer patients: A study in Chinese cohort

  2020cites this paper
• Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

  2019cites this paper
• Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers

  2019cites this paper
• Pharmacogenetics and Cancer Treatment: Progress and Prospects

  2019cites this paper
• Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma.

  2018cites this paper
• SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand

  2018cites this paper
• ERCC1 rs11615 polymorphism increases susceptibility to breast cancer: a meta-analysis of 4547 individuals

  2018cites this paper
• Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis

  2017cites this paper
• Polymorphism in ERCC1 confers susceptibility of coronary artery disease and severity of coronary artery atherosclerosis in a Chinese Han population

  2017cites this paper
• DNA Damage Repair and TP53 Gene in Platinum-drug Resistance

  2016cites this paper
• Cadernos de Anatomia Patológica Pathology Notebooks

  2016cites this paper
• An investigation of the pharmacogenetic basis of toxicity to platinum chemotherapy agents

  2016cites this paper
• Nucleotide excision repair pathway gene polymorphisms are linked to breast cancer risk in a Chinese population

  2016cites this paper
• A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy

  2016cites this paper
• Cisplatin resistance and opportunities for precision medicine.

  2016cites this paper
• Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study

  2016cites this paper
• Role of ubiquitination of ERCC1 in DNA repair in melanoma

  2015cites this paper
• Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis

  2014cites this paper
• Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?

  2014cites this paper
• Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.

  2014cites this paper
• Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.

  2014cites this paper
• DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance

  2014cites this paper
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

  2014cites this paper
• Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours

  2013cites this paper
• Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

  2013cites this paper
• Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.

  2013cites this paper
• MTHFR Glu429Ala and ERCC5 His46His Polymorphisms Are Associated with Prognosis in Colorectal Cancer Patients: Analysis of Two Independent Cohorts from Newfoundland

  2013cites this paper
• Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.

  2012cites this paper
• The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes.

  2012cites this paper
• Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study.

  2012cites this paper
• Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.

  2012cites this paper
• Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.

  2012cites this paper
• Linking The Multiple Functions of XPF-ERCC1 Endonuclease in DNA Repair to Health Outcomes: Cancer and Aging

  2012cites this paper
• Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia

  2012cites this paper
• Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

  2012cites this paper
• ERCC1 intron 1 was associated with breast cancer risk

  2012cites this paper
• SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients.

  2011cites this paper
• Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

  2011cites this paper
• Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

  2011cites this paper
• Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

  2011cites this paper
• Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.

  2011cites this paper
• Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer.

  2011cites this paper
• The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.

  2011cites this paper
• 5 Current insights in the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anti-cancer drugs

  2011cites this paper
• Genetic polymorphisms of genes involved in DNA repair and metabolism influence micronucleus frequencies in human peripheral blood lymphocytes.

  2011cites this paper
• Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer

  2011cites this paper
• Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.

  2011cites this paper
• Imunolocalização, metilação e polimorfismo do gene ERCC1 em carcinoma espinocelular de cabeça e pescoço: correlação com parâmetros clínicos, controle locorregional e sobrevida

  2011cites this paper
• Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection

  2011cites this paper
• DNA-repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival

  2011cites this paper
• Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.

  2011cites this paper
• Part 1: background, methodology, and clinical adoption of pharmacogenetics.

  2011cites this paper
• Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.

  2011cites this paper
• Pharmacogenetics in Colorectal Cancer

  2010cites this paper
• Caractérisation pharmacogénétique des facteurs de résistance et de toxicité de l'Oxaliplatine et de l'Irinotécan dans les tumeurs colorectales

  2010cites this paper
• The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer

  2010cites this paper
• Damage and Repair in Translational Oncology : Overview

  2010cites this paper
• Damage and Repair in Translational Oncology : Overview Reed ract

  2010cites this paper
• ERCC1-XPF nuclease: Roles in the repair of DNA interstrand crosslinks and chemotherapy resistance

  2010cites this paper
• DNA Damage and Repair in Translational Oncology: An Overview

  2010cites this paper
• Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.

  2010cites this paper
• Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

  2009cites this paper
• Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy

  2009cites this paper
• DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

  2009cites this paper
• ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX‐4 treatment in Asian patients with metastatic colorectal carcinoma

  2009cites this paper
• [ERCC1 and RRM1 genes in lung cancer].

  2009cites this paper
• Pharmacogenetics in chemotherapy of colorectal cancer.

  2009cites this paper
• Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment

  2009cites this paper
• Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1

  2008cites this paper
• ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.

  2008cites this paper
• ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

  2008cites this paper
• Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis

  2008cites this paper
• The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer

  2008cites this paper
• Pharmaco(epi)genomics in ovarian cancer.

  2008cites this paper
• ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.

  2008cites this paper
• Pharmacogenetics in Cancer Management: Scenario for Tailored Therapy

  2008cites this paper
• DNA Polymorphisms Affecting Chemosensitivity Toward Drugs

  2008cites this paper
• Colorectal cancer therapeutics and the challenges of applied pharmacogenomics.

  2007cites this paper
• Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs

  2007cites this paper
• ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.

  2007cites this paper
• Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis

  2007cites this paper
• Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.

  2007cites this paper
• Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer

  2007cites this paper
• Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma

  2007cites this paper
• Association between nucleotide excision repair gene polymorphisms and chromosomal damage in coke-oven workers

  2007cites this paper
• Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

  2007cites this paper
• [Association between nucleotide excision repair gene polymorphisms and chromosomal damage in coke-oven workers].

  2006cites this paper
• Molecular mechanisms of mammalian global genome nucleotide excision repair.

  2006cites this paper
• Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population.

  2006cites this paper
• Genome wide analysis of dna repair by expression profiling

  2006cites this paper
• Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

  2006cites this paper
• A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer

  2006cites this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cites this paper